Free tool
FAERS Monitor: Steglujan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209805 or its brand name (Steglujan, Ertugliflozin, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.
Reports
120
Serious
75
63% of reports
Hospitalization
45
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea16
- bradycardia15
- vomiting15
- covid-1913
- covid-19 pneumonia12
- gastrointestinal haemorrhage12
- blood glucose increased10
- cardiac failure9
- product dose omission issue9
- hypertension6
- no adverse event6
- ketoacidosis5
- rash5
- alopecia4
- diabetic neuropathy4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 6 |
| 2019 | 28 |
| 2020 | 30 |
| 2021 | 13 |
| 2022 | 4 |
| 2023 | 20 |
| 2024 | 14 |
| 2025 | 2 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| covid-19 pneumoniaSignal | 12 | 178.3 | 104.2 | 1,941 |
| diabetic neuropathySignal | 4 | 141.7 | 54.1 | 427 |
| ketoacidosisSignal | 5 | 117.2 | 49.7 | 465 |
| bradycardiaSignal | 15 | 49.6 | 30.9 | 668 |
| gastrointestinal haemorrhageSignal | 12 | 25.2 | 14.7 | 256 |
| cardiac failureSignal | 9 | 19.7 | 10.5 | 142 |
| covid-19Signal | 13 | 13.0 | 7.8 | 133 |
| blood glucose increasedSignal | 10 | 9.3 | 5.1 | 67 |
| no adverse eventSignal | 6 | 5.8 | 2.7 | 19 |
| vomitingSignal | 15 | 5.6 | 3.5 | 53 |
| product dose omission issueSignal | 9 | 5.4 | 2.9 | 28 |
| hypertensionSignal | 6 | 5.0 | 2.3 | 15 |
| dyspnoeaSignal | 16 | 5.0 | 3.1 | 48 |
| alopeciaSignal | 4 | 3.6 | 1.4 | 5 |
| rash | 5 | 2.0 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.